All In Biotech

Drug Trial Radar · NCT03701399

Troriluzole in Adult Participants With Spinocerebellar Ataxia

A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia.

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 299 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

299

Actual

Start

Mar 8, 2019

Primary completion

Feb 18, 2022

Study completion Aug 3, 2026

Sponsor

Lead sponsor
Biohaven Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).

Conditions

  • Spinocerebellar Ataxias
  • Spinocerebellar Ataxia Type 1
  • Spinocerebellar Ataxia Type 2
  • Spinocerebellar Ataxia Type 3
  • Spinocerebellar Ataxia Type 6
  • Spinocerebellar Ataxia Type 7
  • Spinocerebellar Ataxia Type 8
  • Spinocerebellar Ataxia Type 10

Interventions

  • troriluzoleDrug

    Administered orally

  • PlaceboDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Randomization Phase: Change From Baseline in the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Total Score at Week 48 in SCA ParticipantsTime frame: Randomization Baseline; Week 48

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • CNS Trials

    Long Beach, California

  • UCLA

    Los Angeles, California

  • UCSF

    San Francisco, California

  • University of Colorado Hospital

    Aurora, Colorado

  • University of Florida Health

    Gainesville, Florida

  • Mayo Clinic Florida

    Jacksonville, Florida

  • University of South Florida

    Tampa, Florida

  • Emory

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Northwest Neurology, Ltd.

    Rolling Meadows, Illinois

  • Johns Hopkins Medicine

    Lutherville, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Columbia University

    New York, New York

  • Duke University Movement Disorders Clinic

    Durham, North Carolina

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Houston Methodist

    Houston, Texas

  • Swedish Health Services

    Seattle, Washington

  • Central South University Xiangya Hospital

    Changsha, Hunan, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.